{"": [203, 1911, 0], "Introduction": [1912, 7282, 0], "Demographic factors": [8203, 11118, 0], "Comorbidities": [11119, 12870, 0], "Environment": [12871, 14076, 0], "Vaccine responses": [14077, 15574, 0], "High risk population for COVID-19": [7283, 15574, 1], "Lessons from the PrEP strategy for HIV": [15575, 17568, 0], "Molnupiravir": [18434, 20728, 0], "Remdesivir": [20729, 23445, 0], "Favipiravir": [23446, 25008, 0], "Tenofovir-based regimens": [25009, 27325, 0], "Nirmatrelvir/ritonavir": [27326, 28911, 0], "Azvudine": [28912, 30742, 0], "Consideration for PrEP for COVID-19": [17569, 30742, 1], "Perspectivs and challenges for PrEP for COVID-19": [30743, 37677, 0], "Conclusion": [37678, 39197, 0], "Author contributions": [39198, 39515, 0], "Funding": [39516, 39875, 0], "Conflict of interest": [39876, 40071, 0], "Publisher's note": [40072, 40437, 0]}